484 articles in this topic
A new strategy combining a TROP2-targeting drug with osimertinib may delay the inevitable resistance that undermines EGFR-mutant lung cancer treatment.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
New research reveals how chronic stress recruits immunosuppressive macrophages from bone marrow into brain tumors, accelerating glioma progression.
A landmark ACSM consensus statement delivers the first evidence-based exercise guidelines for children and adolescents during and after cancer treatment.
PathPrism uses interpretable AI to find spatial biomarkers in colorectal cancer slides, predicting survival, mutations, and chemo benefit.
A landmark Cell study reveals that the patient's own immune system—not just CAR T cells—decides outcomes in recurrent glioblastoma.
A comprehensive review reveals how combining genomics, proteomics, and metabolomics is uncovering new AML targets and improving patient outcomes.
A major review reveals how inflammaging and immunosenescence synergistically drive colorectal cancer in older adults, reshaping the tumor microenvironment.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
A sweeping review of CAR-T and CAR-NK cell therapies in acute myeloid leukemia, covering clinical trial outcomes, key targets, and next-gen strategies.
A phase 1 study finds paricalcitol combined with chemotherapy shows early promise against metastatic pancreatic cancer.
A 13-modality molecular analysis of 173 AML patients reveals distinct subtypes, metabolic reprogramming, and a machine-learning-validated therapy target.
